Directory
>
John Johnson
John Johnson
Board Director | Reaction Biology
United States
John Johnson
Summary
John Johnson is an accomplished executive with extensive experience in the biotechnology and pharmaceutical industries. As the current CEO and Board Director of Reaction Biology, he has a proven track record of leadership in various organizations, including Axogen and Xeris Pharmaceuticals. With a career spanning over three decades, John has held pivotal roles such as Chief Executive Officer at Melinta Therapeutics and Strongbridge Biopharma. His expertise in commercial physical research and biopharmaceuticals is complemented by his educational background from the University of Rochester and East Stroudsburg University. Known for his strategic vision, John is passionate about driving innovation and improving patient outcomes through advanced therapies. His board memberships across multiple companies showcase his commitment to the growth of the biotech sector. John's leadership style emphasizes collaboration and mentorship, fostering a culture of excellence in the teams he leads. He is a sought-after expert in the industry, often sharing insights on the future of drug development and commercialization.
John Johnson
Work Experience
Board Director at
Reaction Biology
March 2022 - Present
Board Member at
Xeris Pharmaceuticals
October 2021 - Present
Chairman at
AUTOLUS LIMITED
September 2021 - Present
Board Member at
axogen
January 2021 - Present
Board Member at
Verastem Oncology
April 2020 - Present
Board Member at
360biolabs, a BioAgilytix company
November 2018 - December 2021
Chief Executive Officer at
STRONGBRIDGE BIOPHARMA LIMITED
July 2020 - October 2021
Board Member at
Portola Pharmaceuticals
March 2014 - July 2020
Chief Executive Officer at
Melinta Therapeutics
February 2019 - August 2019
Board Member at
Histogenics
November 2013 - February 2019
Board Member at
AVEO Oncology
February 2018 - February 2019
Lead Independenr Director at
Sucampo Pharmaceuticals LLC
December 2014 - February 2018
Chairman, President, And Chief Executive Officer at
Dendreon
January 2012 - August 2014
Health Section Governing Board Member at
Biotechnology Innovation Organization
January 2013 - August 2014
Chairman at
Tranzyme Pharma
December 2010 - July 2013
Chief Executive Officer at
Savient Pharmaceuticals
January 2011 - January 2012
President Of Global Oncology at
Eli Lilly
September 2009 - January 2011
Chief Executive Officer at
Imclone Systems A Wholly Owned Subsidiary Of Eli Lilly
August 2007 - September 2009
Company Group Chairman, Worldwide Biopharmaceuticals at
JOHNSON AND JOHNSON (PTY) LTD
January 2005 - July 2007
President at
Ortho Biotech, Inc.
January 2003 - January 2005
Wwvp Cns at
JOHNSON AND JOHNSON (PTY) LTD
November 2001 - April 2003
Vp, Anti-Infectives/Analgesics/Neuroscience at
Ortho Mcneil Pharmaceutical
January 1998 - January 2000
District Sales Manager at
PFIZER PHARMACEUTICALS (HONGKONG) LIMITED
January 1987 - January 1988
John Johnson
Education
University of Rochester - Simon Business School
January 1984 - January 1986
East Stroudsburg University of Pennsylvania, Bachelor Of Science (Bs)
January 1978 - January 1981
January 1976 - January 1978
Frequently Asked Questions about John Johnson
What is John Johnson email address?
John Johnson's primary email address is *********@autolus.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does John Johnson work for?
John Johnson is a Board Director at Reaction Biology, a company specializing in Commercial physical research.
Where John Johnson graduated from?
John Johnson holds a degree in from University of Rochester - Simon Business School .
How can I directly contact John Johnson?
To contact John Johnson directly, you can use the email address *********@autolus.com. Complete contact information is available upon registration with Muraena.
Who is John Johnson?
John Johnson is an accomplished executive with extensive experience in the biotechnology and pharmaceutical industries. As the current CEO and Board Director of Reaction Biology, he has a proven track record of leadership in various organizations, including Axogen and Xeris Pharmaceuticals. With a career spanning over three decades, John has held pivotal roles such as Chief Executive Officer at Melinta Therapeutics and Strongbridge Biopharma. His expertise in commercial physical research and biopharmaceuticals is complemented by his educational background from the University of Rochester and East Stroudsburg University. Known for his strategic vision, John is passionate about driving innovation and improving patient outcomes through advanced therapies. His board memberships across multiple companies showcase his commitment to the growth of the biotech sector. John's leadership style emphasizes collaboration and mentorship, fostering a culture of excellence in the teams he leads. He is a sought-after expert in the industry, often sharing insights on the future of drug development and commercialization.
John`s contact details
*********@autolus.com
********@axogeninc.com
************@reactionbiology.com
Colleagues
Chief Science Officer
Vice President, Finance
Chief Of Staff
CEO/ Managing Director, Reaction Biology Europe GmbH
Vice President of Global Scientific Operations
Vice President of Corporate Development
Chief People Officer